These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 26016480)

  • 21. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
    Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
    Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
    Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma.
    Tsutsumi K; Sato N; Tanabe R; Mizumoto K; Morimatsu K; Kayashima T; Fujita H; Ohuchida K; Ohtsuka T; Takahata S; Nakamura M; Tanaka M
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S491-9. PubMed ID: 21837532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel prognostic factor TIPE2 inhibits cell proliferation and promotes apoptosis in pancreatic ductal adenocarcinoma (PDAC).
    Sun Y; Cao S; Li Z; Liu X; Xu J; Tian Y; Shen S; Zhou Y
    Int J Med Sci; 2021; 18(9):2051-2062. PubMed ID: 33850476
    [No Abstract]   [Full Text] [Related]  

  • 26. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
    PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
    Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
    Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma.
    Ben QW; Wang JC; Liu J; Zhu Y; Yuan F; Yao WY; Yuan YZ
    Ann Surg Oncol; 2010 Aug; 17(8):2213-21. PubMed ID: 20162456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma.
    Thomas RM; Truty MJ; Kim M; Kang Y; Zhang R; Chatterjee D; Katz MH; Fleming JB
    Ann Surg Oncol; 2015; 22(6):1884-92. PubMed ID: 25404477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum EpCAM expression in pancreatic cancer.
    Gebauer F; Struck L; Tachezy M; Vashist Y; Wicklein D; Schumacher U; Izbicki JR; Bockhorn M
    Anticancer Res; 2014 Sep; 34(9):4741-6. PubMed ID: 25202052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival.
    Nizri E; Sternbach N; Bar-David S; Ben-Yehuda A; Gerstenhaber F; Ofir T; Wolf I; Weiner G; Lahat G; Klausner J
    Ann Surg Oncol; 2018 Feb; 25(2):475-481. PubMed ID: 29124488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma.
    Gao Y; Wang M; Guo X; Hu J; Chen TM; Finn SMB; Lacy J; Kunstman JW; Cha CH; Bellin MD; Robert ME; Desir GV; Gorelick FS
    PLoS One; 2021; 16(9):e0250539. PubMed ID: 34587190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
    Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pyruvate Kinase Muscle Isoenzyme 2 (PKM2) Expression Is Associated with Overall Survival in Pancreatic Ductal Adenocarcinoma.
    Lockney NA; Zhang M; Lu Y; Sopha SC; Washington MK; Merchant N; Zhao Z; Shyr Y; Chakravarthy AB; Xia F
    J Gastrointest Cancer; 2015 Dec; 46(4):390-8. PubMed ID: 26385349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The combination of strong immunohistochemical mtTFA expression and a high survivin index predicts a shorter disease-specific survival in pancreatic ductal adenocarcinoma.
    Kimura T; Kitada S; Uramoto H; Zhi L; Kawatsu Y; Takeda T; Horie S; Nabeshima A; Noguchi H; Sasaguri Y; Izumi H; Kohno K; Yamada S
    Histol Histopathol; 2015 Feb; 30(2):193-204. PubMed ID: 25108120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic significance of clinicopathological features and apoptosis inhibitor proteins in pancreas ductal adenocarcinoma.
    Argon A; Nart D; Oruç N; Coker A; Ozütemiz O
    Acta Gastroenterol Belg; 2014 Jun; 77(2):229-34. PubMed ID: 25090821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma.
    Poruk KE; Firpo MA; Huerter LM; Scaife CL; Emerson LL; Boucher KM; Jones KA; Mulvihill SJ
    Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2605-10. PubMed ID: 20729288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
    Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
    Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.